Weekly <i>nab</i>-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

Socinski, Mark A.; Bondarenko, Igor; Karaseva, Nina; Makhson, Anatoly; Vynnychenko, I.; Okamoto, Isamu; Hon, Jeremy K.; Hirsh, Vera; Bhar, Paul; Zhang, Hui; Iglesias, J.; Renschler, Markus F.

doi:10.1200/jco.2011.39.5848

Cited by 668 publications

(677 citation statements)

References 21 publications

Supporting

Mentioning

625

Contrasting

Unclassified

Order By: Relevance

“…There was an approximately 10% improvement in the median PFS (6.3 vs. 5.8 months; p=0.214) and overall survival rate (12.1 Japanese institutes (149 patients) participated in the above international phase III trial and they reported significant improvement in median PFS (6.9 vs. 5.6 months) in the nabpaclitaxel arm vs. standard paclitaxel arm. 16) However, no improvement in median overall survival was observed (16.7 vs. 17.2 months) in the nab-paclitaxel arm vs. the standard paclitaxel arm, respectively. 16) 4. cHARAcTERISTIc SIDE EFFEcTS 4.1.…”

Section: Patients With Non-small Cell Lung Cancermentioning

confidence: 83%

“…16) However, no improvement in median overall survival was observed (16.7 vs. 17.2 months) in the nab-paclitaxel arm vs. the standard paclitaxel arm, respectively. 16) 4. cHARAcTERISTIc SIDE EFFEcTS 4.1. Liposomal Doxorubicin Although some studies showed that liposomal doxorubicin is less toxic than other second-line chemotherapy regimens for ovarian cancer, liposomespecific side effects such as various skin and hypersensitivity reactions were reported in addition to severe myelosuppression.…”

Section: Patients With Non-small Cell Lung Cancermentioning

confidence: 83%

“…16) In that study, 1,052 untreated patients with stage IIIB to IV nScLc were randomly assigned to receive nab-paclitaxel 100 mg/m 2 weekly and carboplatin at area under the concentration time curve (AUC) 6 once every 3 weeks or standard paclitaxel 200 mg/ m 2 plus carboplatin AUC 6 once every 3 weeks. The nabpaclitaxel arm demonstrated a significantly higher ORR than the standard paclitaxel arm (33% vs. 25%; p=0.005).…”

Section: Patients With Non-small Cell Lung Cancermentioning

confidence: 99%

See 2 more Smart Citations

Clinical Application of Drug Delivery Systems in Cancer Chemotherapy: Review of the Efficacy and Side Effects of Approved Drugs

Iwamoto

2013

Biological & Pharmaceutical Bulletin

219

133

View full text Add to dashboard Cite

In recent years, drug delivery systems (DDS) have been developed, along with anticancer agents for those systems based on the concept of achieving a better clinical response and tolerability. Several clinical trials have shown that these drugs have better clinical effects in the treatment of many cancers, leading to their expanded indications. Liposomal doxorubicin is one DDS agent used to treat AIDS-related Kaposi's sarcoma and ovarian cancer in Japan. In addition to those two indications, the Food and Drug Administration (FDA) approved this drug for the treatment of multiple myeloma in 2007. Another DDS agent approved in Japan is nanoparticle albumin-bound paclitaxel, which has been used in the treatment of breast cancer. Most recently, this drug has been approved for the treatment of non-small cell lung cancer in the U.S.A. Although these DDS agents appear to be less toxic than conventional drugs, DDS-specific side effects such as various skin reactions, hypersensitivity reaction, and peripheral neuropathy sometimes occur. Therefore, medical staff must understand DDS anticancer agents fully, including characteristic side effects, to achieve the desired clinical outcomes.

show abstract

Section: Patients With Non-small Cell Lung Cancermentioning

confidence: 83%

Section: Patients With Non-small Cell Lung Cancermentioning

confidence: 83%

Section: Patients With Non-small Cell Lung Cancermentioning

confidence: 99%

See 1 more Smart Citation

Clinical Application of Drug Delivery Systems in Cancer Chemotherapy: Review of the Efficacy and Side Effects of Approved Drugs

Iwamoto

2013

Biological & Pharmaceutical Bulletin

219

133

View full text Add to dashboard Cite

show abstract

“…More recently, a phase III clinical trial on MBC patients was conducted where 260 mg/ m 2 nap-paclitaxel was applied every week compared to 175 mg/ m 2 of paclitaxel every 3 week, and was found to show significant improvement in outcomes including overall response rate (ORR), time of tumor progression (TTP) and progression free survival (PFS) [11,53]. According to this data, nab-paclitaxel dose of 260 mg/ m 2 every 3 week has obtained an approval for use in MBC in more than 40 countries [54,55]. Furthermore, nab-paclitaxel has been shown to reduce drug exposure to healthy tissue [43].…”

Section: Dosage Bioavailability and Therapeutic Index In Mbcmentioning

confidence: 99%

Untitled

2017

MOJCSR

View full text Add to dashboard Cite

Breast cancer (BC) remains the most invasive diagnosed cancers among female, affecting 25% of total number of cancers worldwide. Systematic chemotherapies still remain one of the effective treatments for BC. One of the common and powerful chemotherapies that have been used in the past decade is taxane. Taxane are a class of anticancer compounds that are known to cause cell cycle arrest and apoptosis induction (cell death). They are used for the treatment of malignant tumors specifically BC along with other chemotherapies such as anthracycline. However, the neurotoxic effects that are associated with the use of taxane are still challenging. Recently, nanoparticle albumin bound taxane (nab-paclitaxel) was developed, resulting in lowering of the side effects that are associated with the use of taxane and enhancing its delivery to the targeted cancer cells. Nab-paclitaxel has been subjected to several clinical trials to evaluate its efficacy in the treatment of various types of cancers including BC. The results indicated that nab-paclitaxel showed an improved efficacy and promising outcomes in the treatment of various forms of BC. This review focuses on the comparison of classical taxane to the new generation, nab-paclitaxel chemotherapy, with emphasis on their comparative efficacy in metastatic BC (MBC) and triple negative metastatic BC (TNMBC) treatment, concluding that nab-paclitaxel has improved efficacy, safety data and with a more convenient administration confirming an optimal treatment option for patients in both cases. Future work is needed to optimize dosing schedules and combination regimens of nab-paclitaxel, which could broaden the clinical utility of this agent.

show abstract

“…More recently, additional agents have been approved in combination with platinum in this setting including pemetrexed and nab-paclitaxel. [1][2][3] One particular advance in the last decade has been the recognition that histology should be considered in the choice of initial chemotherapy. This was discovered after an additional analysis of two studies showed pemetrexed to be more effective in non-squamous histologies and less active in squamous tumors.…”

mentioning

confidence: 99%

Second-Line Chemotherapy and Beyond for Non–Small Cell Lung Cancer

Durm

Hanna

2017

Hematology/Oncology Clinics of North America

View full text Add to dashboard Cite

Keywordsnon-small cell lung cancer, chemotherapy, second-line treatment, docetaxel, pemetrexed, erlotinib Key Points• Docetaxel, pemetrexed, and erlotinib are approved for the second-line treatment of NSCLC.• The discovery of targetable mutations, the increasing use of maintenance strategies, and the introduction of immunotherapies has made the choice of second-line agents much more complicated.• Ramucirumab with docetaxel is the only combination regimen that has shown improved overall survival in the second-line setting.• Erlotinib is the only agent approved in the third-line setting for EGFR wild-type patients. First Line TreatmentIn patients without targetable genetic alterations, the standard first-line therapy for advanced (stage IIIB or IV) NSCLC is chemotherapy with a platinum doublet for 4-6 cycles with or without bevacizumab. 1 Historically, a number of drugs including paclitaxel, docetaxel, gemcitabine, and vinorelbine were considered acceptable platinum partners in the first-line metastatic setting with essentially no differences in progression free survival (PFS) or overall survival (OS). More recently, additional agents have been approved in combination with platinum in this setting including pemetrexed and nab-paclitaxel. [1][2][3] One particular advance in the last decade has been the recognition that histology should be considered in the choice of initial chemotherapy. This was discovered after an additional analysis of two studies showed pemetrexed to be more effective in non-squamous histologies and less active in squamous tumors. 3-5 Based on these findings, the choice of first-line agents in metastatic NSCLC is now strongly based on presenting histology, and this initial choice affects available second-line options. Maintenance TherapyHistorically, patients treated with first-line platinum doublet chemotherapy who had objective responses or stable disease were placed on surveillance following completion of 4-6 cycles. However, over the last decade, new data suggests that there is benefit to the addition of maintenance therapy following initial chemotherapy. There are two maintenance strategies including continuation of an agent used in the first-line setting or switching to a previously unused agent (switch maintenance). There is data supporting the use of bevacizumab, pemetrexed, and erlotinib in the maintenance setting either as single agents or in combination. [6][7][8][9][10][11] Prior maintenance therapy is of particular importance when discussing second-line chemotherapy options as the use of maintenance therapy, particularly when switch maintenance is employed, influences the availability of agents in the second-line setting and beyond. Chemotherapy as Second-Line TreatmentHistorically, nearly all patients received platinum doublet chemotherapy followed by single agent chemotherapy in the second-line setting. However, with the discovery of targetable mutations, the development of tyrosine kinase inhibitors (TKI), the increasing use of maintenance strategies, and the introduction of imm...

show abstract

Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

Abstract: The administration of nab-PC as first-line therapy in patients with advanced NSCLC was efficacious and resulted in a significantly improved ORR versus sb-PC, achieving the primary end point. nab-PC produced less neuropathy than sb-PC.

Cited by 668 publications

References 21 publications

Clinical Application of Drug Delivery Systems in Cancer Chemotherapy: Review of the Efficacy and Side Effects of Approved Drugs

Clinical Application of Drug Delivery Systems in Cancer Chemotherapy: Review of the Efficacy and Side Effects of Approved Drugs

Untitled

Second-Line Chemotherapy and Beyond for Non–Small Cell Lung Cancer

Contact Info

Product

Resources

About